Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

TCT 700: Drug-Loss at Arterial Bends Can Dominate Off-Target Drug Delivery by Paclitaxel-Coated Balloons

Presentation TCT 2024

TCT 700: Drug-Loss at Arterial Bends Can Dominate Off-Target Drug Delivery by Paclitaxel-Coated Balloons

Presenter: Linnea Tscheuschner

October 29, 2024

BTK Drug Coated Balloons: 1 Year After LIFE BTK – We Need Them More Than Ever

Presentation TCT 2024

BTK Drug Coated Balloons: 1 Year After LIFE BTK – We Need Them More Than Ever

Presenter: Peter Schneider

October 28, 2024

What’s Going to Be Big at TCT 2024?

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

FDA Approves Bioresorbable Scaffold for BTK Lesions

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

News Daily News

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

April 24, 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

News Conference News ACC 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

April 10, 2024

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

News Daily News

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

March 25, 2024

Will IVUS Ever Take Off in Peripheral Vascular Interventions?

News Conference News ISET 2024

Will IVUS Ever Take Off in Peripheral Vascular Interventions?

January 31, 2024

How to Reconcile BEST-CLI and BASIL-2? A ‘Patient-First’ Strategy

News Conference News ISET 2024

How to Reconcile BEST-CLI and BASIL-2? A ‘Patient-First’ Strategy

January 24, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.